EbsArgent

EbsArgent is a first-in-class bactericidal antibiotic for urinary tract infections (UTIs) caused by antibiotic-resistant bacteria. It uses a novel mechanism of action, combining silver ions and ebselen to disable the bacterial thioredoxin enzyme system. This approach aims to combat the growing global health threat of multidrug-resistant UTIs.

Funding Round: Series A

Funding Amount: $2.4M

Date: 30-Oct-2024

Investors: Mikael Lรถnn, MD, Jens Mogensen, GU Ventures, Vasa Angels, Annexstruktur, Gobia Enterprises

Markets: Pharmaceuticals, Antibiotic, Healthtech

HQ: Solna, Stockholm, Sweden

Founded:

Website: http://www.thioredoxinsystems.com/

LinkedIn:

Twitter:

Instagram:

Facebook:

Crunchbase:

Pitchbook:


Similar Startups


Leave a Comment

    ๐Ÿ”ท Buy VC Database ๐ŸŸฉ Buy Startup Database ๐ŸŽ Get Free Sample

    Share this: